Immuron Limited · ASX:IMC
Immuron — Kalkine Media Webinar (July 2026)
17 slides from Immuron's conference presentation, Jul 20, 2026
Slide 1: Immuron CEO presentation at Kalkine Media Webinar
Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar Melbourne, Australia, July 20, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Kalkine Media Webinar on Monday 20th July 2026 (12:30pm
Slide 2: Immuron Platform Technology
Immuron Platform Technology Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine
Slide 3: ProIBS, IBS market and references
them. 91% of the users experienced an improvement in daily life and 98% would recommend PROIBS® to someone else. To learn more please check: www.proibs.eu. Irritable bowel syndrome (IBS) is a common condition where you experience symptoms related to your digestive system. This is sometimes linked to
Slide 4: Steven Lydeamore, Chief Executive Officer
NASDAQ: IMRN ASX: IMC For personal use only Investor Presentation Steven Lydeamore Chief Executive Officer 20 July 2026
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r t a i n s t a t e m e nt s m a d e i n t h i s p re s e nt a t i o n a re fo r wa rd - l o o k i n g s t a t e m e nt s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c t a t i o n s , e s t i m a t e s a n d p ro j e c t i o n s . Wo rd s s u c h a s “a nt i
Slide 6: Immuron integrated biopharmaceutical company overview
Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral products for the treatment of gut mediated diseases For personal use only Technology Research & Technology Platform Development Global Corporate Platform Safe and pot
Slide 7: Executive summary
Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company Overview For personal use only Two commercial products: Travelan® (traveler’
Slide 8: The Immuron Investment Thesis
The Immuron Investment Thesis Immuron is a commercial-stage biopharmaceutical company (NASDAQ: IMRN) using a proprietary "Hyper- Immune" platform to create naturally-derived, oral antibody therapies for gut health and infectious diseases. For personal use only The Competitive “Moat” • Consistent Rev
Slide 9: Growth Catalysts & Competitive Edge
Growth Catalysts & Competitive Edge • Broad Platform Utility: This isn't a one-trick pony. The technology can be applied to a range of infectious diseases, creating a deep pipeline of potential drug candidates. For personal use only • High Barrier to Entry: The company’s proprietary vaccination prot
Slide 10: Immuron strategic reset provides clearer path to profitability
Immuron strategic reset provides clearer path to profitability Immuron has taken a strategic decision to partner clinical assets IMM-124E and IMM-529 for development and commercialization. For personal use only • IMM-124E is eligible for an end of Phase 2 meeting with the U.S. FDA (indication: trave
Slide 11: IMM-529: A First-in-Class Triple-Action CDI Biologic
IMM-529: A First-in-Class Triple-Action CDI Biologic The Opportunity: IMM-529 is an oral, non-systemic biological (hyperimmune bovine colostrum) for treatment and prevention of primary and recurrent Clostridioides difficile infection (CDI). Unlike antibiotics, IMM-529 eliminates For personal use onl
Slide 12: IMM-529 Market Potential
IMM-529 Market Potential The Disease: C. difficile is the leading cause of healthcare-associated For personal use only infection causing 400,000 cases and 30,000 deaths in the US annually Disease spectrum: • Mild-to-moderate: Watery persistent diarrhea, cramping • Severe/Pseudomembranous Colitis (PM
Slide 13: IMM-529 Deal Potential
IMM-529 Deal Potential Licensor / Asset Stage at Year Licensee / Acquirer Licensed Asset Financial terms (public) Status update (as of March 2026) Owner deal For personal use only Asset sale signed Aug 2024 (public reporting FDA approved (Apr 2023) and commercialized by VOWST (SER-109) indicates dea
Slide 14: Financial & Operational Highlights
For personal use only 1. FINANCIAL & OPERATIONAL HIGHLIGHTS
Slide 15: Continued strong sales growth
Continued strong sales growth Global For personal use only + FY2026 AUD$7.7 million up 6% on prior year Australia + FY2026 AUD$5.8 million up 10% on prior year North America + FY2026 AUD$1.9 million down 5% on prior year + USA FY2026 AUD$1.8 million up 7% on prior year; up 13% in USD + Canada FY2026
Slide 16: Commercial – Operational Highlights
Commercial – Operational Highlights 2H FY26 and 1H FY25 2H FY25 1H FY26 Outlook For personal use only Travelan® / Protectyn® / PROIBS® • $3.99m Global sales • $3.29m Global sales • $4.18m Global sales • $3.53m global sales Revenue • $2.89m Australia • $2.36m Australia • $3.27m Australia • $2.51m Aus
Slide 17: Steven Lydeamore contact information
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172